BioRestorative shares surge 12.01% intraday on positive Phase 2 data and FDA Phase 3 alignment.

BioRestorative Therapies surged 12.01% intraday after announcing positive blinded Phase 2 data for BRTX-100, showing meaningful improvements in pain and function for chronic lumbar disc disease, alongside alignment with the FDA on Phase 3 trial design. The company will present the data at the 2026 Orthopaedic Research Society Annual Meeting on March 28, with a pre-market press release. The FDA raised no safety concerns and confirmed the CMC framework’s suitability for late-stage development, reinforcing progress toward commercialization. The news highlights the therapy’s regenerative potential and regulatory clarity, fueling investor optimism about the pipeline’s advancement.